Head-to-head · WeighScore
Direct Meds vs MyStart Health
The verdict
Direct Meds takes it — 82.6/100 to 67.1/100.
Direct Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the few programs offering an oral/sublingual route alongside injectable — semaglutide from ~$179 sublingual (~$297 injectable), tirzepatide ~$224/$399, with an intro promo near $147, all-inclusive and no membership.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Direct Meds | MyStart Health |
|---|---|---|
| WeighScore | 82.6/100 | 67.1/100 |
| Grade | B− | C |
| Scorecard rank | #19 | #176 |
| Semaglutide | $179/mo | $299/mo (all doses, compounded) |
| Tirzepatide | $224/mo | $299/mo (all doses, compounded) |
| Coverage | Not publicly listed | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
Graded #19 · B−
Strengths
- Rare oral/sublingual option in addition to injectable
- All-inclusive pricing with no separate membership fee
- Both molecules — semaglutide and tirzepatide
- Intro promotional pricing near $147
Where it loses points
- Compounded only — not FDA-approved
- Pricing is company-stated, not independently live-verified
- Newer and somewhat ambiguous (operates across multiple domains)
- States served are not disclosed
Graded #176 · C
Strengths
- Price Lock Guarantee — your $299 base rate doesn't rise as your dose escalates
- Fast onboarding: roughly 5-minute intake, 24-hour prescription turnaround, 2–4 day shipping
- 24/7 care team access with unlimited clinician messaging included
- LegitScript certified
- Clear Section 503A compounding disclosure on every landing page
Where it loses points
- Not BBB accredited — C+ rating with 10 complaints, mostly shipping delays and support access
- Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- Markets oral tirzepatide, but no FDA-approved oral tirzepatide exists
- Very new company (incorporated May 2024) with a limited track record
- Pharmacy partners not named, so 503A compliance can't be independently verified
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.